Pyrukynd
Payments companies reported to CMS as associated with Pyrukynd. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pyrukynd, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pyrukynd
These are the largest totals companies reported as associated with Pyrukynd. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sherif Badawy | Chicago, IL | Pediatric Hematology-Oncology | $108,776.45 |
| Biree Andemariam | Farmington, CT | Hematology & Oncology | $93,957.77 |
| Sujit Sheth | New York, NY | Pediatric Hematology-Oncology | $90,783.52 |
| Steven Fein | Miami, FL | Hematology & Oncology | $85,483.92 |
| Rachael Grace | Boston, MA | Pediatric Hematology-Oncology | $47,856.06 |
| John Wood | Los Angeles, CA | Pediatric Cardiology | $47,145.34 |
| Stephanie Fritch Lilla | Minneapolis, MN | Pediatric Hematology-Oncology | $46,909.26 |
| Alexander Glaros | Detroit, MI | Pediatric Hematology-Oncology | $43,369.35 |
| Hanny Al-Samkari | Boston, MA | Hematology & Oncology | $42,016.12 |
| Matthew Vander Heiden | Boston, MA | Hematology & Oncology | $40,000.00 |
Prescribed Pyrukynd?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.